These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19283632)

  • 1. Harm reduction policies in Argentina: a critical view.
    Epele ME; Pecheny M
    Glob Public Health; 2007; 2(4):342-58. PubMed ID: 19283632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug use, harm reduction, and health policies in Argentina: obstacles and new perspectives.
    Inchaurraga S
    Clin Infect Dis; 2003 Dec; 37 Suppl 5():S366-71. PubMed ID: 14648449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vulnerable among the vulnerable: drug users in situations of poverty and indigence in Argentina.
    Vivas LE; Radulich G; Bruno D
    Clin Infect Dis; 2003 Dec; 37 Suppl 5():S358-61. PubMed ID: 14648447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The children of mama coca: coca, cocaine and the fate of harm reduction in South America.
    Bastos FI; Caiaffa W; Rossi D; Vila M; Malta M
    Int J Drug Policy; 2007 Mar; 18(2):99-106. PubMed ID: 17689352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The social context of initiation into injecting drugs in the slums of Makassar, Indonesia.
    Nasir S; Rosenthal D
    Int J Drug Policy; 2009 May; 20(3):237-43. PubMed ID: 18554892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 'Social evils' and harm reduction: the evolving policy environment for human immunodeficiency virus prevention among injection drug users in China and Vietnam.
    Hammett TM; Wu Z; Duc TT; Stephens D; Sullivan S; Liu W; Chen Y; Ngu D; Des Jarlais DC
    Addiction; 2008 Jan; 103(1):137-45. PubMed ID: 18028519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Republic of Argentina: Argentina is the envy of other Latin American countries.
    Spain D
    Int Demogr; 1984 May; 3(5):4-8. PubMed ID: 12313038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving access to pharmaceuticals in Brazil and Argentina.
    Homedes N; Ugalde A
    Health Policy Plan; 2006 Mar; 21(2):123-31. PubMed ID: 16415339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of joined-up HIV harm reduction and multidrug resistant tuberculosis control programmes in Estonia: System dynamics simulation model.
    Atun RA; Lebcir RM; McKee M; Habicht J; Coker RJ
    Health Policy; 2007 May; 81(2-3):207-17. PubMed ID: 16854499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strengthening drug policy and practice through ethics engagement: an old challenge for a new harm reduction.
    Irwin KS; Fry CL
    Int J Drug Policy; 2007 Mar; 18(2):75-83. PubMed ID: 17689348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Speech by Oscar Julian Bardeci, director of the Centro Latinoamericano de Demografia (CELADE), at the Latinamerican Regional Meeting prior to the International Conference on Population in recognition of the Second Meeting on Population by the Committee of Upper-Level Government Experts (CEGAN), Havana, Cuba, November 16-19, 1983].
    Bardeci OJ
    Notas Poblacion; 1983 Dec; 11(33):151-64. PubMed ID: 12339528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Theorizing "Big Events" as a potential risk environment for drug use, drug-related harm and HIV epidemic outbreaks.
    Friedman SR; Rossi D; Braine N
    Int J Drug Policy; 2009 May; 20(3):283-91. PubMed ID: 19101131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normalization and harm reduction: research avenues and policy agendas.
    Erickson PG; Hathaway AD
    Int J Drug Policy; 2010 Mar; 21(2):137-9. PubMed ID: 20022234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Putting at risk what we know: reflecting on the drug-using subject in harm reduction and its political implications.
    Moore D; Fraser S
    Soc Sci Med; 2006 Jun; 62(12):3035-47. PubMed ID: 16413645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal timing of use reduction vs. harm reduction in a drug epidemic model.
    Caulkins JP; Tragler G; Wallner D
    Int J Drug Policy; 2009 Nov; 20(6):480-7. PubMed ID: 19361975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harm reduction actions as a health care construction process at a public health center in Rosario, Argentina.
    Lavarello D; Lottero M; Chavero M; Toledo A; Espínola M; Gerlero S; Liborio M
    Clin Infect Dis; 2003 Dec; 37 Suppl 5():S353-7. PubMed ID: 14648446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New toxics, new poverty: a social understanding of the freebase cocaine/Paco in Buenos Aires, Argentina.
    Epele ME
    Subst Use Misuse; 2011; 46(12):1468-76. PubMed ID: 21707470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing prevalence of HIV, and persistent high-risk behaviours among drug users in Bangladesh: need for a comprehensive harm reduction programme.
    Islam MM; Conigrave KM
    Drug Alcohol Rev; 2007 Jul; 26(4):445-54. PubMed ID: 17564883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 'Individual' harms, Community 'harms': reconciling Indigenous values with drug harm minimisation policy.
    van der Sterren AE; Anderson IP; Thorpe LG
    Drug Alcohol Rev; 2006 May; 25(3):219-25. PubMed ID: 16753645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Merseyside, the first harm reduction conferences, and the early history of harm reduction.
    O'Hare P
    Int J Drug Policy; 2007 Mar; 18(2):141-4. PubMed ID: 17689357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.